Assessment of dynamic susceptibility contrast cerebral blood flow response to amphetamine challenge: A human pharmacological magnetic resonance imaging study at 1.5 and 4 T

Magnetic Resonance in Medicine

Volumn 55, Issue 1, 2006, Pages 9-15

  Rose, Stephen E ^a   Janke, Andrew L ^a   Strudwick, Mark W ^a   McMahon, Katie L ^a   Chalk, Jonathan B ^a   Snyder, Peter ^b   De Zubicaray, Greig I ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Amphetamine; CBF; DSC perfusion; MRI; Superparamagnetic nanoparticles

Indexed keywords

DRUG DELIVERY; HEMODYNAMICS; IRON OXIDES; MAGNETIC NANOPARTICLES; MAGNETIC RESONANCE IMAGING; MAGNETIC SUSCEPTIBILITY; NEUROPHYSIOLOGY; SUPERPARAMAGNETISM;

AMPHETAMINE; CENTRAL NERVOUS SYSTEMS; DOPAMINERGIC PATHWAYS; DSC PERFUSION; DYNAMIC SUSCEPTIBILITY CONTRAST; HEMODYNAMIC RESPONSE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES; SUPERPARAMAGNETIC NANOPARTICLES;

BLOOD;

AMPHETAMINE; SUPERPARAMAGNETIC IRON OXIDE;

ADULT; ARTICLE; BRAIN BLOOD FLOW; CONTRAST ENHANCEMENT; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG EFFICACY; DYNAMIC SUSCEPTIBILITY CONTRAST PERFUSION IMAGING; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; LIMBIC CORTEX; MALE; NEUROPHYSIOLOGY; NIGRONEOSTRIATAL SYSTEM; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING;

EID: 30344446357     PISSN: 07403194     EISSN: None     Source Type: Journal    
DOI: 10.1002/mrm.20749     Document Type: Article

References (21)

1. Jenkins BG, Chen Y, Mandeville JB. Pharmacological magnetic resonance imaging (phMRI). In: van Bruggen N, Roberts T, editors. Biomedical imaging in experimental neuroscience. New York: CRC Press; 2003. p 155-209.
2. Silva AD, Zhang W, Williams DS, Koretsky AP. Multislice MRI of rat brain during amphetamine stimulation using arterial spin labeling. Magn Reson Med 1995;33:209-214.
3. Leslie RA, James MF. Pharmacological magnetic resonance imaging; a new application for functional MRI. Trends Pharmacol Sci 2000;21:314-318.
4. Carlsson C, Hagerdal M, Siesjo BK. Influence of amphetamine sulfate on cerebral blood flow and metabolism. Acta Physiol Scand 1975;94:128-129.
5. Devous MD, Trivedi MH, Rush AJ. Regional cerebral blood flow response to oral amphetamine challenge in healthy volunteers. J Nucl Med 2001;42:535-542.
6. Chen YI, Mandeville JB, Nguyen TV, Talele A, Cavagna F, Jenkins BG. Improved mapping of pharmacologically induced neuronal activation using the IRON technique with superparamagnetic blood pool agents. J Magn Reson Imaging 2001;14:517-524.
7. 15O PET in baboons: before and after amphetamine. J Nucl Med 2002;43:1090-1100.
8. Simonsen CZ, Ostergaard L, Vestergaard-Poulsen P, Rohl E, Bjornerud A, Gyldensted C. CBF and CBV measurements by USPIO bolus tracking: Reproducibility and comparison with Gd-based values. J Magn Reson Imaging 1999;9:342-347.
9. Sun Y, Yang D, Ye Q, Williams M, Moura JM, Boada F, Liang ZP, Ho C. Improving spatiotemporal resolution of USPIO-enhanced dynamic images of rat kidneys. Magn Reson Imaging 2003;21:593-598.
10. Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin Pharmacol Ther 1971;12:245-258.
11. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893-897.
12. Collins DL, Neelin P, Peters TM, Evans AC. "Automatic 3-D intersubject registration of MR volumetric data in standardized Talairach space." J Comput Assis Tomogr 1994;18:192-205.
13. Ostergaard L, Weisskoff RM, Chester DA, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages, part I: mathematical approach and statistical analysis. Magn Reson Med 1996;36:715-725.
14. Rose SE, Janke AL, Griffin M, Finnigan S, Chalk JB. Improved prediction of final infarct volume using bolus delay-corrected perfusion-weighted MRI: implications for the ischemic penumbra. Stroke 2004;35:2466-2471.
15. Worsley K, Lao CH, Aston J, Petre V, Duncan GH, Morales F, Evans AC. A general statistical approach for fMRI data. Neuroimage 2002;15:1-15.
16. Calamante F, Gadian DG, Connelly A. Quantification of perfusion using bolus tracking magnetic resonance imaging in stroke; assumptions, limitations and potential implications for clinical use. Stroke 2002;33:1146-1151.
17. Penny WD, Stephan KE, Mechelli A, Friston KJ. Modeling functional integration: A comparison of structural equation and dynamic causal models. Neuroimage 2004;23:264-274.
18. 15O positron emission tomography. J Cereb Blood Flow Metab 2002;22:1149-1156.
19. 2O PET in humans. J Cereb Blood Flow Metab 1998;18:935-940.
20. Henry ME, Kaufman MJ, Lange N, Schmidt ME, Purcell S, Cote J, Perron-Henry DM, Stoddard E, Cohen BM, Renshaw PF. Test-retest reliability of DSC MRI CBV mapping in healthy volunteers. Neuroreport 2001;12:1567-1569.
21. Mattay VS, Berman KF, Ostrem JL, Esposito G, Van Horn JD, Bigelow LB, Weinberger DR. Dextroamphetamine enhances "Neural Network-Specific" physiological signals: a positron-emission tomography rCBF study. J Neurosci 1996;16:4816-4822.